Clinica Chimica Acta最新文献

{"title":"Nanoparticle electrochemical biosensors for virus detection","authors":"Anandavalli Baskar ,&nbsp;Keerthana Madhivanan ,&nbsp;Raji Atchudan ,&nbsp;Sandeep Arya ,&nbsp;Ashok K. Sundramoorthy","doi":"10.1016/j.cca.2024.120054","DOIUrl":"10.1016/j.cca.2024.120054","url":null,"abstract":"<div><div>Viruses pose a significant threat to global public health, underscoring the urgent need for rapid, accurate, and sensitive diagnostic methods for timely detection and intervention. The demand for efficient diagnostics that can detect a wide range of viral pathogens has never been greater. In this context, metal nanoparticle-based biosensors have emerged as a promising solution, offering exceptional sensitivity for detecting various analytes, including nucleic acids (DNA/RNA), proteins, and other biomarkers associated with pathogens. These biosensors are particularly critical for the development of point-of-care (POC) diagnostic tools, enabling early detection of infectious agents. This review explores recent advancements in nanoparticle (NP)-based biosensors that utilize noble metals like gold (Au), silver (Ag), and platinum (Pt) for viral pathogen detection, focusing on viruses such as SARS-CoV, HIV, hepatitis, influenza, and Zika. It highlights the role of NP-based electrochemical sensors and compares traditional and contemporary detection techniques. The review also examines key performance metrics such as limits of detection (LOD), linear detection ranges, cost-effectiveness, and accessibility, with a special emphasis on their application in POC diagnostics. The aim is to provide researchers with valuable insights into the development of next-generation NP-based biosensors, facilitating the creation of innovative diagnostic technologies for viral diseases.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120054"},"PeriodicalIF":3.2,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cortisol quantification in human plasma and urine by liquid chromatography coupled to mass spectrometry: Validation, analysis and application in a reference population and patients with adrenal incidentalomas","authors":"Andressa Cristina dos Santos Marques ,&nbsp;Bruna Brito ,&nbsp;Jéssica Gorett Brito Fontes ,&nbsp;Gabriel Reis Alves Carneiro ,&nbsp;João Felipe Dickson Rebelo ,&nbsp;Aline Barbosa Moraes ,&nbsp;Leonardo Vieira Neto ,&nbsp;Monica Costa Padilha","doi":"10.1016/j.cca.2024.120055","DOIUrl":"10.1016/j.cca.2024.120055","url":null,"abstract":"<div><div>Cortisol is a glucocorticoid hormone, which is involved in cardiovascular, metabolic, inflammatory and behavioral processes in the human body. Immunoassays, used for routine analysis of analytes, usually lead to erroneous quantification due to the low specificity of these methods. In this study, we developed LC-MS/MS methods with surrogating matrices for evaluating cortisol in both urine and plasma samples and validated them according to Brazilian Health Regulatory Agency guidelines. Urine samples were prepared with an enzymatic hydrolysis stage, followed by a solid-phase extraction (C18 cartridges) using dichloromethane:methanol 9:1 as elution solvent. Plasma samples were prepared by protein precipitation with acetonitrile, using 50 μL of sample. HPLC was performed using a C8 column under 300 mL min⁻¹ flow gradient conditions with water and methanol, both containing 5 mM ammonium formate and 0.1 % formic acid. Mass spectrometer with electrospray ionization in positive mode and selected reaction monitoring as detection technique were employed. Calibration curves were linear over a concentration range of 1–200 ng mL-1 for urine (r² = 0.9950) and 0.5–300 ng mL-1 for plasma (r² = 0.9970). The methods were selective, showed suitable precision, accuracy, and sensibility (limit of quantification = 0.85 ng mL⁻¹ for urine and 0.15 ng mL⁻¹ for plasma). Validated methods were successful applied to 22 real samples and a cohort of patients [n = 63 urines and n = 79 plasmas (from the Clementino Fraga Filho University Hospital, Rio de Janeiro, Brazil)].</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120055"},"PeriodicalIF":3.2,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases","authors":"Naoki Morishima ,&nbsp;Maki Iwaisako ,&nbsp;Yoshihiro Kamada ,&nbsp;Miyako Nakano ,&nbsp;Masafumi Shiida ,&nbsp;Tatsuya Ono ,&nbsp;Reika Sonoda ,&nbsp;Risa Uemura ,&nbsp;Daisuke Sakon ,&nbsp;Munefumi Shimosaka ,&nbsp;Shinji Takamatsu ,&nbsp;Jumpei Kondo ,&nbsp;Takeo Yoshihara ,&nbsp;Shinichiro Shinzaki ,&nbsp;Eiji Mita ,&nbsp;Tetsuo Takehara ,&nbsp;Takashi Kumada ,&nbsp;Makoto Yamada ,&nbsp;Eiji Miyoshi","doi":"10.1016/j.cca.2024.120052","DOIUrl":"10.1016/j.cca.2024.120052","url":null,"abstract":"<div><div>Galactose-deficient (agalactosyl) IgG is significantly increased in the serum of patients with rheumatoid arthritis, and autoantibodies against it are used in clinical tests. Subsequent studies also show increased agalactosyl IgG in many chronic inflammatory diseases. In this study, we generated antibody 42B1 recognizing agalactosyl IgG and developed a new method to evaluate chronic inflammatory diseases with it. Using an ELISA with antibody 42B1, we measured serum levels of agalactosyl IgG in 32 patients with inflammatory bowel disease (IBD), 60 patients with chronic liver disease, 60 patients with chronic pancreatitis, and 32 subjects undergoing health checkups who did not have IBD. Serum agalactosyl IgG levels were increased in all patients with chronic inflammations and partially correlated with clinical parameters. Among the subjects undergoing health checkups, some subjects showed a 15 % elevation of serum agalactosyl IgG levels, suggesting possible latent chronic inflammation. Future studies will examine the 42B1 antibody ELISA in various autoimmune diseases. Altogether, the 42B1 antibody for determination of serum agalactosyl IgG levels is a novel diagnostic tool for chronic inflammation.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120052"},"PeriodicalIF":3.2,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of glycation biomarkers in human fingernails by isotope-dilution liquid chromatography tandem mass spectrometry (LC-MS/MS)","authors":"Frédéric J. Tessier ,&nbsp;Sarahi Jaramillo Ortiz ,&nbsp;Dinh Hieu Nguyen ,&nbsp;Kamel Mohammedi ,&nbsp;Cécile Delcourt ,&nbsp;Catherine Helmer ,&nbsp;Mélanie Le Goff ,&nbsp;Eric Boulanger ,&nbsp;Vincent Rigalleau ,&nbsp;Michael Howsam","doi":"10.1016/j.cca.2024.120036","DOIUrl":"10.1016/j.cca.2024.120036","url":null,"abstract":"<div><div>Glycation is a non-enzymatic, post-translational modification of proteins which is elevated in several pathologies, notably diabetes. An early-stage glycation product, glycated hemoglobin (HbA1c), is used in the clinical management of diabetes, and advanced glycation end-products (AGEs) are implicated in the etiology of diabetic complications. Fingernail clippings contain a time-integrated repository of several metabolic processes during the preceding 3–5 months, are easily sampled, and various elements and molecules have been shown to remain stable within them for long periods without refrigeration.</div><div>Building upon a few underexploited studies, we investigated fingernails as a non-invasive matrix to assess glycation using liquid chromatography–mass spectrometry to quantify ungual biomarkers of early- and advanced glycation (respectively furosine, as a fructose-lysine derivative, and two AGEs (N<em>^ε</em>-carboxymethyllysine (CML) and N<em>^ε</em>-carboxyethyllysine (CEL)). The method was appropriately validated and provided accurate and precise measurements of two amino acids and the glycation biomarkers. Sample storage at ± 25 °C for 12 months had no effect upon these analytes, and the method was applied to fingernails from 87 people with diabetes.</div><div>There was a moderate, linear correlation between ungual furosine concentrations and HbA1c at the time of nail sampling (<strong><em>r_s</em></strong> = 0.339, <em>p</em> = 0.0011). Among subjects for whom previous measurements were available, there was no correlation between ungual glycation and HbA1c measured &gt; 3 months before nail sampling, indicating that ungual furosine reflects early-stage glycation over a similar period to HbA1c. This study provides further evidence, using modern analytical techniques, that fingernails offer the possibility to quantitatively and non-invasively assess glycation.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120036"},"PeriodicalIF":3.2,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrochemical biosensors for dopamine","authors":"Hang Zhu ,&nbsp;Guifen Xu","doi":"10.1016/j.cca.2024.120039","DOIUrl":"10.1016/j.cca.2024.120039","url":null,"abstract":"<div><div>Dopamine (DA), a key catecholamine, plays a pivotal role in the regulation of human cognition and emotions. It has profound effects on the hormonal, memory, and cardiovascular systems. Anomalies like Alzheimer’s, Parkinson’s, schizophrenia, and senile dementia are linked to abnormal DA levels. Consequently, the precise determination of DA levels in biological systems is critical for the accurate diagnosis and treatment of these disorders. Among all analytical techniques, electrochemical studies provide the most selective and highly sensitive methods for detecting DA in biological samples. Ascorbic acid and uric acid are two examples of small biomolecules that can obstruct the detection of DA in biological fluids. To address this issue, numerous attempts have been made to modify bare electrodes to separate the signals of these substances and enhance the electrocatalytic activity towards DA. Various surface modifiers, including coatings, conducting polymers, ionic liquids, nanomaterials, and inorganic complexes, have been employed in the modification process. Despite the reported success in DA detection using electrochemical sensors, many of these approaches are deemed too complex and costly for real-world applications. Therefore, this review aims to provide an overview of DA electrochemical biosensors that are practical for real-world applications.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120039"},"PeriodicalIF":3.2,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-center study on the application potential of Siaα-2,6Gal in early and differential diagnosis of lung cancer","authors":"Si Yue ,&nbsp;Yuhan Chen ,&nbsp;Wenhao Cui ,&nbsp;Xiuwei Lu ,&nbsp;Yuhuan Shen ,&nbsp;Feifei Zhou ,&nbsp;Jinju Guan ,&nbsp;Jierong Chen ,&nbsp;Qiuyuan Wen ,&nbsp;Yongjian Chen","doi":"10.1016/j.cca.2024.120031","DOIUrl":"10.1016/j.cca.2024.120031","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to investigate the application potential of the abnormal glycan structure Siaα-2,6Gal in the early and differential diagnosis of lung cancer.</div></div><div><h3>Methods</h3><div>Clinical data and serum samples from 730 patients and 120 healthy individuals participating in clinical trials on Siaα-2,6Gal were collected at three medical centers between January 2022 and June 2023. The levels of Siaα-2,6Gal, carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen (CYFRA21-1), squamous cell carcinoma antigen (SCC), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (ProGRP) in serum were measured. The application potentials of these markers in the early and differential diagnosis, classification, and staging of lung cancer were explored.</div></div><div><h3>Results</h3><div>(1) Serum Siaα-2,6Gal levels in the lung cancer group were 2,606 (1,970–3,458) U/mL, significantly higher than those in the benign lung disease, miscellaneous malignant tumor, miscellaneous benign disease, and healthy individual groups at 1,359 (950–1,528), 1,252 (903–1,532), 1,196 (850–1,490), and 1,210 (1,100–1,287) U/mL (P &lt; 0.0001). (2) Serum Siaα-2,6Gal levels in the early-stage lung cancer (stages 0–II) group were 2,576 (1,929–3,338) U/mL, significantly higher than those in the benign pulmonary nodule group at 1,419 (1,105–1,820) U/mL (P &lt; 0.0001). (3) Receiver operating characteristic curves showed that Siaα-2,6Gal had a high diagnostic efficiency for lung cancer (area under the curve (AUC) = 0.9217), significantly superior to CEA, CYFRA21-1, SCC, NSE, and ProGRP (AUCs of 0.6618, 0.6605, 0.5783, 0.5985, and 0.6381).</div></div><div><h3>Conclusion</h3><div>Siaα-2,6Gal is a promising biomarker for lung cancer diagnosis and may offer superior differential diagnosis of early-stage lung cancer from benign pulmonary nodules compared to traditional tumor markers.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120031"},"PeriodicalIF":3.2,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LC-MS/MS method for quantification of 23 TKIs in Plasma: Assessing the relationship between anlotinib trough concentration and toxicities","authors":"Chen Bu ,&nbsp;Liansheng Jiang ,&nbsp;Lili Cui ,&nbsp;Mao Tang ,&nbsp;Xinhua Song ,&nbsp;Yingkui Zhao ,&nbsp;Zhengyan Liang ,&nbsp;Liya Ye ,&nbsp;Jiayao Nian ,&nbsp;Shouhong Gao ,&nbsp;Xia Tao ,&nbsp;Zhipeng Wang ,&nbsp;Wansheng Chen","doi":"10.1016/j.cca.2024.120028","DOIUrl":"10.1016/j.cca.2024.120028","url":null,"abstract":"<div><h3>Objectives</h3><div>To develop a simple, rapid, and sensitive LC-MS/MS method for quantifying 23 tyrosine kinase inhibitors (TKIs) in plasma samples, and evaluate the relationship between the trough concentration of anlotinib(ANL) and its toxicities.</div></div><div><h3>Methods</h3><div>The method was developed in Agilent 1290–6460 UHPLC-MS/MS system. This study prospectively enrolled 55 cancer patients undergoing ANL treatment. Plasma samples were collected at steady-state trough concentration and subsequently analyzed using the method. Patients were recorded for the occurrence of toxicities. Statistical analysis was performed to assess the association of the toxicities with ANL exposure level and patients’ characteristics.</div></div><div><h3>Results</h3><div>The LC-MS/MS method was developed and validated for all items required by pharmacopoeia. The results revealed a positive association between the trough concentration of ANL and the incidence of toxicities. The exposure level 17.655 ng/mL (AUC 0.82, p = 0.010) was identified as a predictive threshold value for grade ≥ 3 overall toxicities. In addition, lower platelet count (PLT count &lt; 179 × 10⁹ g/L) was significantly associated with higher occurrence of grade ≥ 3 toxicities (AUC 0.75, p = 0.049). A logistic model incorporating these two factors demonstrated improved diagnostic capacity for predicting ≥ 3 overall toxicities (AUC = 0.90, p = 0.001).</div></div><div><h3>Conclusions</h3><div>This study successfully developed and validated a simple, rapid, and sensitive LC-MS/MS method for quantifying 23 TKIs in plasma samples. Besides, this study found that both C_trough of ANL and PLT count as independent predictors for ANL-induced ≥ 3 overall toxicities. Moreover, a logistic model including these two factors presents better prediction capacity for ≥ 3 overall toxicities.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120028"},"PeriodicalIF":3.2,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long non-coding RNAs in pancreatic cancer","authors":"Yuan Chen,&nbsp;Xiaohua Ye,&nbsp;Minli Hu,&nbsp;Yibing Hu,&nbsp;Jin Ding","doi":"10.1016/j.cca.2024.120040","DOIUrl":"10.1016/j.cca.2024.120040","url":null,"abstract":"<div><div>This article reviews the recent advances in pathogenesis, diagnosis and treatment of pancreatic cancer, as well as the relationship between long non-coding RNA (lncRNA) in disease progression. Unfortunately, pancreatic cancer has no early symptoms and quickly invades surrounding tissue and organs, making it one of the deadliest. Accordingly, we urgently need to identify high-risk individuals with precancerous lesions through screening methods to identify early disease, provide better prevention strategies and improve overall survival. LncRNAs have a variety of biological functions in both physiologic and pathophysiologic states including tumor growth, differentiation and proliferation. Herein we review the biological functions, expression patterns, clinical significance and targeted therapy potential of lncRNAs to provide new approaches for diagnosis and treatment in pancreatic cancer.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120040"},"PeriodicalIF":3.2,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating liver health with metabolomics: A comprehensive review","authors":"Preetpal Singh,&nbsp;Ravinder Singh,&nbsp;Chirag Pasricha,&nbsp;Pratima Kumari","doi":"10.1016/j.cca.2024.120038","DOIUrl":"10.1016/j.cca.2024.120038","url":null,"abstract":"<div><div>Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease worldwide, affecting one-fourth of the world’s population. With more than half of the world’s population, the Asia-Pacific region contributed 62.6 % of liver-related fatal incidents in 2015. Currently, liver imaging techniques such as computed tomography (CT), nuclear magnetic resonance (NMR) spectroscopy, and ultrasound are non-invasive imaging methods to diagnose the disease. A liver biopsy is the gold standard test for establishing the definite diagnosis of non-alcoholic steatohepatitis (NASH). However, there are still significant problems with sample variability and the procedure’s invasiveness. Numerous studies have indicated various non-invasive biomarkers for both fibrosis and steatosis to counter the invasiveness of diagnostic procedures. Metabolomics could be a promising method for detecting early liver diseases, investigating pathophysiology, and developing drugs. Metabolomics, when utilized with other omics technologies, can result in a deeper understanding of biological systems. Metabolomics has emerged as a prominent research topic, offering extensive opportunities to investigate biomarkers for liver diseases that are both sensitive and specific. In this review, we have described the recent studies involving the use of a metabolomics approach in the diagnosis of liver diseases, which would be beneficial for the early detection and treatment of liver diseases.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120038"},"PeriodicalIF":3.2,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and heterogeneity of antinuclear antibody patterns in adult Italian patients with autoimmune liver diseases: Our experience","authors":"Caterina Maria Gambino ,&nbsp;Luisa Agnello ,&nbsp;Vincenza Calvaruso ,&nbsp;Rosaria Vincenza Giglio ,&nbsp;Luigi Capodicasa ,&nbsp;Concetta Scazzone ,&nbsp;Giuseppina Candore ,&nbsp;Fabio Del Ben ,&nbsp;Vito Di Marco ,&nbsp;Marcello Ciaccio","doi":"10.1016/j.cca.2024.120037","DOIUrl":"10.1016/j.cca.2024.120037","url":null,"abstract":"<div><h3>Background and aim</h3><div>This study aims to explore the clinical significance of antinuclear antibodies (ANA) patterns in liver diseases.</div></div><div><h3>Materials and methods</h3><div>We included 396 patients with a request for ANA testing for suspected autoimmune liver disease (AILD). For each patient, we collected demographical, clinical, and laboratory data.</div></div><div><h3>Results</h3><div>Among the patients, 33% had AILD, predominantly aiutoimmune hepatitis (AIH). The AC1 pattern was significantly more prevalent in AIH patients, while the AC21 pattern was strongly associated with primary biliary cholangitis (PBC). AC4-AC5 patterns were less frequent in AIH and PBC patients but more common in non-alcoholic hepatitis. Elevated alkaline phosphatase and gamma-glutamyl transferase levels were observed in AILD patients with AC11, AC12, and AC21 patterns.</div></div><div><h3>Conclusions</h3><div>These findings highlight the different distribution of ANA patterns in liver diseases, with specific patterns showing strong associations with distinct liver conditions.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120037"},"PeriodicalIF":3.2,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}